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Abstract
Background: Species identification of isolates belonging to the Mycobacterium tuberculosis complex (MTC) seems to 
be important for the appropriate treatment of patients, since M. bovis is naturally resistant to a first line anti-tuberculosis 
(TB) drug, pyrazinamide, while most of the other MTC members are susceptible to this antimicrobial agent. A simple 
and low-cost differentiation method was needed in higher TB burden countries, such as Bangladesh, where the 
prevalence of M. bovis among people or cattle has not been investigated.
Methods: Genetic regions cfp32, RD9 and RD12 were chosen as targets for a species distinguishable multiplex PCR and 
the system was evaluated with twenty reference strains of mycobacterial species including non-tubercular 
mycobacteria (NTM). A total of 350 clinical MTC isolates obtained in Bangladesh were then analyzed with this multiplex 
PCR.
Results: All of the MTC reference strains gave expected banding patterns and no non-specific amplifications were 
observed in the NTM strains. Out of 350 clinical isolates examined by this method, 347 (99.1%) were positive for all of 
the cfp32, RD9 and RD12 and determined as M. tuberculosis. Two isolates lacked cfp32 PCR product and one lacked 
RD12, however, those three samples were further examined and identified as M. tuberculosis by the sequence analyses 
of hsp65 and gyrB.
Conclusions: The MTC-discrimination multiplex PCR (MTCD-MPCR) developed in this study showed high specificity 
and was thought to be very useful as a routine test because of its simplicity. In the current survey, all the 350 MTC 
isolates obtained from Bangladesh TB patients were determined as M. tuberculosis and no other MTC were detected. 
This result suggested the general TB treatment regimen including pyrazinamide to be the first choice in Bangladesh.
Background
Mycobacterium tuberculosis complex (MTC), including
M. tuberculosis, M. bovis, M. africanum, M. microti, M.
pinnipedii, M. caprae, "M. canettii" and other closely
related strains, is a group of causative agents for human
and animal tuberculosis (TB) [1,2]. Although the myco-
bacterial species in MTC are highly similar to each other
in DNA level, MTC members differ widely in terms of
host tropism, phenotype and pathogenicity [1,3-5]. No
further differentiation is usually performed with isolates
determined as MTC, however, it seems to be important
in some cases for the appropriate management of patients
or for an epidemiological purpose. Especially, in the case
of M. bovis infection, to identify the species in the early
stage of diagnosis is essential to avoid inappropriate treat-
ment, since M. bovis is naturally resistant to a major anti-
TB drug, pyrazinamide [3,4,6], and the standard regimen
including this drug has to be altered.
Several rapid identification methods using nucleic acid
amplification techniques have been developed and used
for the diagnosis of TB [7-9], however, they do not differ-
entiate  M. tuberculosis from other members of MTC.
Recent comparative genomic analyses have provided
valuable information on the region of difference (RD) in
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the chromosome of MTC to indicate that specific identi-
fication of MTC can be achieved by the detection of these
regions [1-3,10]. PCR-based methods targeting RDs can
be easily performed in local clinical laboratories with low
expense [3].
Bangladesh is one of the highest TB burden countries,
where the estimated number of TB incidence in 2007 was
353,000 to be ranked sixth in the world in the WHO
report [11]. In this country, a large number of cattle esti-
mated 23 million heads are reared in households espe-
cially in rural areas [12]. Some surveys about drug
resistant M. tuberculosis [13,14] or M. tuberculosis epide-
miology [15] have been performed, however, no survey
about M. bovis prevalence among humans as well as cat-
tle has been reported though people are living in a close
relationship with cattle [12,16].
In this study, we developed a simple multiplex-PCR sys-
tem, named MTC-discrimination multiplex PCR
(MTCD-MPCR), to distinguish M. tuberculosis from
other MTC species using RDs, and applied it for clinical
isolates derived from TB patients in Bangladesh.
Methods
Bacterial strains and sample collection
For the evaluation of the method, following twenty refer-
ence strains, four MTC strains and sixteen nontubercu-
lous mycobacteria (NTM) strains, were obtained from
the Research Institute of Tuberculosis, Japan Anti-Tuber-
culosis Association (Tokyo, Japan) and used: M. tubercu-
losis  H37Rv,  M. africanum KK13-02,  M. microti
ATCC19422, M. bovis BCG Tokyo, M. avium JATA51-01,
M. intracellulare JATA52-01, M. kansasii KK21-01, M.
xenopi  KK42-02, M. fortuitum JATA61-01, M. lentifla-
vum  JATA9N-01,  M. simiae KK23-01,  M. gordonae
JATA33-01,  M. marinum JATA22-01,  M. asiaticum
KK24-01,  M. scrofulaceum JATA31-01,  M. szulgai
JATA32-01, M. nonchromogenicum JATA45-01, M. mal-
moense  JATA47-01,  M. chelonae JATA62-01 and M.
abscessus JATA63-01.
Clinical samples were collected in hospitals in Dhaka,
located in an urban area, and Matlab and Sylhet, located
in rural areas. A total of 350 isolates, 300 from Dhaka, 41
from Matlab and 9 from Sylhet, were examined (Addi-
tional file 1). Among them, 327 isolates were derived
from sputa, 22 were from lymph nodes and remaining 1
was from a surgical injury.
Cultivation and biochemical characterization of isolates 
and DNA extraction
Sputa and other samples were collected from TB sus-
pected patients and decontaminated following the
Petropff's method [17]. After a centrifugation at 500 rpm
at 4°C, the supernatant was discarded and one loop-full (5
mm diameter of the loop) decontaminated pellet was
inoculated onto 2 Lowenstein-Jensen (L-J) slants each.
Inoculated L-J slants were incubated at 37°C. Each L-J
slant was examined once a week for contamination as
well as for growth until 8 weeks. Typical mycobacterium-
like colonies were tested for sensitivity to p-nitrobenzoic
(PNB) acid. PNB sensitive strains were considered to be
M. tuberculosis complex. DNA was extracted from those
colonies by heating at 95°C for 5 min followed by chloro-
form extraction and ethanol precipitation [18].
MTC-discrimination multiplex PCR (MTCD-MPCR)
Primer pairs for cfp32  (Rv0577), RD9 (Rv2073c) and
RD12 (Rv3120) designed by Huard et al [3] were slightly
modified and used as a primer mixture for three simulta-
neous PCRs in one tube (Table 1). The reaction mixture
contained 1 mM dNTPs (0.25 mM each), 0.5 M betaine,
750 nM each of cfp32 primers (Rv0577F and Rv0577R),
250 nM each of RD primers (Rv2073cF, Rv2073cR,
Rv3120F and Rv3120R (390-369)), 1 μL of DNA sample
and 1 U of GoTaq DNA Polymerase (Promega Corp., WI,
U.S.A.) in 20 μL of Green GoTaq Reaction Buffer. PCR
reaction was initiated by denaturation for 1 min at 96°C,
followed by 35 cycles of 10 s at 96°C, 20 s at 60°C and 1
min at 72°C with final extension for 5 min at 72°C in a
thermalcycler (iCycler, Bio Rad Laboratories Inc., CA,
U.S.A.). Reaction mixtures with M. tuberculosis DNA and
without template DNA were also run simultaneously with
samples every time as a positive control and a negative
control to evaluate the MTCD-MPCR system. The prod-
u c t s  w e r e  e l e c t r o p h o r e s e d  i n  2 . 0 %  a g a r o s e  g e l  i n  T A E
buffer, and stained with ethidium bromide.
The sensitivity of the method was determined using
serially diluted purified genomic-DNA solutions, ten-fold
dilution from 5 ng/μL to 50 fg/μL, extracted from M.
tuberculosis  H37Rv and M. bovis BCG Tokyo. For the
specificity study, the concentration of the DNA solution
from each reference strain was adjusted to 5 ng/μL and
used.
A detection study from sputum samples was performed
with M. tuberculosis H37Rv spiked sputa. Serially diluted
bacteria were spiked into healthy volunteer's sputum
samples to final concentrations ranging from 1.5 × 10/mL
to 1.5 × 106/mL. The sputum was processed by a conven-
tional method and DNA was extracted by bead-beating.
Briefly, twice the volume of N-acetyl-L-cysteine and
NaOH (NALC-NaOH) was added to the sputum, mixed
well and incubated for 15 minutes. The sample was
diluted to five times its original volume with PBS and
centrifuged for 20 min at 3000 rpm. The sediment was
dissolved in 0.75 mL of Tris-EDTA buffer, added 0.5 g of
glass beads (0.15 - 0.25 mm, Fuji Chemical Industry Co.,
Ltd., Japan) and 0.5 mL of chloroform and then shaken
with a bead-beater (FastPrep FP100A, MP Biomedicals,
U.S.A.) for 5 min at 5500 rpm. Tubes were centrifuged atNakajima et al. BMC Infectious Diseases 2010, 10:118
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Table 1: Used primers for the MTCD-MPCR and additional PCRs and sequencings.
Target locus Primer name Primer sequence Locationa Size (bp) Ref. No.
MTCD-MPCR
cfp32 Rv0577F 5' ATGCCCAAGAGAAGCGAATACAGGCAA 671166-192 786 [3]
Rv0577R 5' CTATTGCTGCGGTGCGGGCTTCAA 671951-928
RD9 Rv2073cF 5' TCGCCGCTGCCAGATGAGTC 2330579-598 600 [3]
Rv2073cR 5' TTTGGGAGCCGCCGGTGGTGATGA 2331173-150
RD12 Rv3120F 5' GTCGGCGATAGACCATGAGTCCGTCTCCAT 3485558-587 404 [3]
Rv3120R (390-369) 5' GCGAAAAGTGGGCGGATGCCAG 3485961-940
Additional PCRs or sequencings
cfp32 3'cfp32F 5' CGAATCATTGGCACGTCTACTTTG 671770-793 372 [2]
3'cfp32R 5' GTGGCACCGGCGGCACCGCACACCT 672141-117
RD12 Rv3120-F (90-110) 5' GGTATTTGCGCCCATATCCTG 3485661-681 411 this study
Rv3120-R (500-481) 5' CCTGGCTTCAAGCACCATTC 3486071-052
rpoB rpoB-Fb 5' CAGGACGTGGAGGCGATCAC 761007-026 250 [18]
rpoB-R 5' CAGGGGTTTCGATCGGGCAC 761256-237
rpoB c rpoB-S-Fb 5' GCGTACGGTCGGCGAGCTGATCC 760922-944 418 this study
rpoB-S-R 5' GCGGTACGGCGTTTCGATGAACC 761339-317
rrs Bact-rrs-Fb 5' AGAGTTTGATCCTGGCTCAG 1471856-875 1496 this study
Bact-rrs-R 5' TACGGCTACCTTGTTACGAC 1473351-332
rrsc rrs-S-Fb 5' ATACCTTTGGCTCCCTTTTCC 1471809-829 1607 this study
rrs-S-R 5' CCCACCAGTTGGGGCGTTTTC 1473415-395
hsp65 hsp65Fb 5' ACCAACGATGGTGTGTCCAT 528752-771 441 [2]
hsp65R 5' CTTGTCGAACCGCATACCCT 529192-173
gyrB gyrBFb 5' ACATCAACCGCACCAAGAACGC 6027-048 483 this study
gyrBR 5' GTGCCTTACGTGCCGCGATACG 6509-488
a Location on the M. tuberculosis H37Rv genome (accession no. NC_000962.2).
b These primers were used for PCR and sequencing.
c Those primer pairs were used for the samples that showed non-MTC gene sequences.
5000 rpm for 5 min and 0.5 mL of PCI (phenol-chloro-
form-isoamyl alcohol, 25:24:1) was added to the superna-
tant, mixed and centrifuged. DNA was extracted from the
PCI treated sample by isopropyl alcohol precipitation and
the precipitant was dissolved in 10 μL of Tris-EDTA buf-
fer. Final solutions were subjected to the MTCD-MPCR.
Other PCRs and Sequence analyses
Additional PCRs and sequencings were performed with
primers listed in Table 1. Reaction solution components
in those PCRs were as follows: 1 mM dNTPs (0.25 mM
each), 0.5 M betaine, 500 nM each of forward and reverse
primers, 1 μL of DNA sample and 1 U of GoTaq DNA
Polymerase (Promega Corp.) in 20 μL of Green Go T aq
Reaction Buffer. PCR reaction other than rrs was initiated
by denaturation for 1 min at 96°C, followed by 30 cycles
of 10 s at 96°C, 10 s at 55°C and 30 sec at 72°C with final
extension for 5 min at 72°C in a thermalcycler (iCycler,
Bio Rad Laboratories Inc.). In rrs  PCR, the period of
extension at 72°C in the cycle was 90 sec, whereas other
conditions were same with other PCR procedure. The
products were electrophoresed in 1.5% agarose gel and
stained with ethidium bromide. Sequencing of PCR prod-
uct was performed according to manufacturer's protocol
with ABI PRISM 3130xl Genetic Analyzer (Life Technol-
ogies Corp., CA, U.S.A.) using BigDye Terminator v3.1
Cycle Sequencing Kit (Life Technologies Corp.). rpoB and
rrs sequences read by each forward primer (T able 1. b)
were compared with the sequence of M. tuberculosis
H37Rv and the samples met following criteria were iden-
tified as MTC: rpoB, more than 98% match in minimum
150-base length; rrs, 100% match in minimum 300 bases.
About the samples determined as non-MTC by these cri-
teria, another PCR and sequencing were done with moreNakajima et al. BMC Infectious Diseases 2010, 10:118
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MTC specific primers (Table 1. c) with the same criteria.
The samples identified as MTC with those specific prim-
ers were determined as mixed-culture samples. Species
identifications by hsp65  or  gyrB  sequences were done
according to previous publications [2,19,20].
Ethical Clearance
The original research project was approved by the
Research Review Committee and Ethical Review Com-
mittee of the International Centre for Diaddroeal Disease
Research, Bangladesh (ICDDR, B). Signed informed con-
sent was obtained from each patient and volunteer
recruited for the study.
Results and discussion
MTCD-MPCR
Three genetic regions were selected as the targets for the
multiplex PCR: cfp32, RD9 and RD12. cfp32 is an MTC-
restricted gene and used to confirm isolates to belong to
MTC [3,21]. RD9 is the region that can be found in only
M. tuberculosis and "M. canettii", and RD12 is found in all
MTC members except M. bovis, M. caprae and "M. canet-
tii" [2,3]. By a trial with several patterns of primer con-
centrations, the best combination was determined to be
750 nM each of cfp32 primers and 250 nM each of RD9
and RD12 primers in the multiplex PCR. With this PCR,
an isolate possessing all the three regions can be identi-
fied as M. tuberculosis whereas a strain showing only one
amplified band, cfp32, will be classified as M. bovis or M.
caprae (Figure 1, Table 2). Other banding patterns are
interpreted as described in Table 2. "M. canettii" is
another MTC that clinical isolates reported so far were
naturally pyrazinamide resistant [6,19]. Thus, this PCR
system was thought to be useful for the discrimination of
MTC species, especially for the screening of naturally
pyrazinamide-resistant species with only one PCR reac-
tion per sample.
The sensitivities of the method were determined as 500
fg genomic DNA for M. tuberculosis (H37Rv) and 50 fg
for M. bovis (BCG Tokyo), which were assumed to be
equivalent to 100 bacilli and 10 bacilli, respectively (data
not shown). The specificity of the MTCD-MPCR was
confirmed with DNA templates extracted from mycobac-
terial reference strains. Typical gel electrophoresis results
of the MTC and NTM strains are shown in Figure 1. All
of the PCR products from the MTC strains gave expected
banding patterns in correct sizes (Table 1). On the con-
trary , no bands were obtained from the NTM samples.
These results demonstrated the specificity and applicabil-
ity of the MTCD-MPCR for the differentiation of M.
tuberculosis in clinical isolates.
In the study using bacterium-spiked sputa, the detec-
tion limit of M. tuberculosis was 1.5 × 104 cells in 1 mL of
sputum (data not shown). This bacterial concentration is
similar or a little higher than the detection limit of the
bacteria by the Zeal-Nelsen staining. This means species
discrimination by the MTCD-MPCR is applicable for
clinical samples if the sputum is diagnosed as smear posi-
tive. The discrepancy of the detection limit between puri-
fied DNA and bacterium-spiked sputum seems to depend
on the extraction or purification procedure, which is to
be improved.
Discrimination of MTC in Bangladesh clinical isolates
A total of 350 clinical isolates obtained in Bangladesh
were analyzed to see the prevalence of MTC species other
than M. tuberculosis. All samples were subjected to rpoB
or  rrs  sequencing to confirm as MTC [22]. By this
sequence analysis, 18 samples were revealed as mixtures
of MTC and other bacteria, mainly mycobacterial spe-
cies. Those mixed samples were also subjected to the
MTCD-MPCR study.
Out of the 350 isolates, 347 (99.1%) showed the typical
banding pattern of M. tuberculosis in the electrophoresis
by the MTCD-MPCR (Table 2). Among three remaining
isolates, one (0.3%, isolate ATP138) lacked RD12 band
showing "M. canettii" pattern and two (0.6%, isolate
M2000 and S2247) did not have cfp32 band, presented as
irregular in Table 2. Those samples were further analyzed
to detect the target region, cfp32 or RD12, with other sets
of primers (Table 1) [2]. With this trial, sample S2247
gave an expected sized cfp32 band, suggesting a partial
deletion or a mutation in the primer-binding site. Other
two samples, ATP138 and M2000, still failed to amplify
the expected DNA fragment indicating that larger dele-
tion event had occurred in the target genomic area.
ATP138, the "M. canettii" pattern sample, was subjected
to hsp65 sequencing and confirmed not to be "M. canet-
tii" [2,19]. These three isolates were further confirmed to
be M. tuberculosis by the sequencing of gyrB [20]. No iso-
lates out of the 350 lacked RD9 band, concordant with the
observations by former researchers [2,10,23], possibly
indicating the high stability of this region in M. tuberculo-
sis. The lack of cfp32 in an MTC isolate has been reported
by Huard et al [2] with a similar incidence (1/125, 0.8%)
to the current study. Some of the mixed-culture samples
showed correct but faint banding patterns, suggesting an
inhibitory effect of contaminated DNA. The result indi-
cated that despite its decreased sensitivity, the MTCD-
MPCR was able to detect MTC from mixed-culture sam-
ples, which sometimes are observed in primary cultures
[8].
All of the 350 MTC isolates obtained from clinical
specimens in Bangladesh were M. tuberculosis and no
other MTC species were detected. This information is
very helpful for the management of patients to determine
treatment regimens. Patients suffered from MTC in sur-
veyed area in Bangladesh can possibly be subjected to theNakajima et al. BMC Infectious Diseases 2010, 10:118
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standard regimen including pyrazinamide. Although M.
bovis  was not detected from human in current study,
there are no precise data about M. bovis prevalence
among cattle in this country, continuous surveys seem to
be needed especially in rural areas where people and cat-
tle inhabit more closely [12]. Since pyrazinamide is sug-
gested to have more adverse side effects than other first-
line anti-TB drugs [24], useless administration to patients
should be avoided.
The MTCD-MPCR developed in this study is consid-
ered to be very useful for the differentiation of MTC
because of its simplicity and specificity. A large number
o f  s a m pl es  can be  a nal yzed by t his m et hod in a s hort
period of time. Some other MTC discrimination methods
using RDs have been published and showed higher differ-
entiation capability that could distinguish almost all
members of MTC. However, the procedures were more
time consuming (e.g., multiple PCR reactions were
needed) [2,3], result interpretations seemed to be compli-
cated (e.g., sizes of amplified bands should be estimated)
[10,23,25] or an expensive equipment should be needed
[26]. The necessity of detailed MTC discrimination seems
to be low since the majority of human tuberculosis caus-
ing agents are M. tuberculosis, and in some global areas,
M. bovis partially contributes to the prevalence [4,23].
The vaccine strain bacillus Calmette-Guerin (BCG), an
attenuated  M. bovis, can be a cause of disseminated
mycobacterial infection in immunocompromised indi-
viduals, however, the patients can be treated by the same
regimen as M. bovis without pyrazinamide [27], and if
necessary, an additional PCR for the detection of RD1 can
distinguish BCG from clinical M. bovis strains [3]. Possi-
bility of the detection of other MTC species is almost
negligible in routine laboratory diagnoses, except for the
cases in some African countries where M. africanum can
be found in a higher ratio [2]. Samples exhibiting rare or
irregular banding patterns by the MTCD-MPCR can be
examined afterward using other precise methods, e.g.,
targeting other RDs, gene sequencing or spoligotyping
[2,19,20,28]. Thus, the MTCD-MPCR, a simple MTC dis-
crimination method developed and evaluated in this
study seemed to be very useful as a screening tool for
clinical isolates to distinguish M. tuberculosis from M.
bovis for the prompt decision of treatment regimen.
Conclusions
In the current study, the MTC-discrimination multiplex
PCR (MTCD-MPCR) was developed and applied for a
Table 2: Results of the MTCD-MPCR with Bangladesh clinical isolates.
Species 
Interpretation
Banding pattern a Number of 
isolates
%
cfp32 RD9 RD12
M. tuberculosis +++ 3 4 7 9 9 . 1
M. bovis/M. caprae +--00
"M. canettii" ++-1   c 0.3
Other MTC b +-+00
Non MTC - - - 0 0
Irregular - + + 2 d 0.6
Total 350 100
a Banding patterns are shown as amplification results of the MTCD-MPCR in order of cfp32, RD9 and RD12: +, Amplification positive; -, 
negative.
b Other MTC includes following species: M. africanum, M. microti, M. pinnipedii, dassie bacillus and oryx bacillus. The latter two are minor strains 
belonging to MTC [2].
c Confirmed to be M. tuberculosis by hsp65 and gyrB sequencing.
d Confirmed to be M. tuberculosis by gyrB sequencing.
Figure 1 Typical MTCD-MPCR banding patterns of mycobacterial 
reference strains. PCR products by the MTCD-MPCR were analyzed 
on 2.0% agarose gel electrophoresis followed by ethidium bromide 
stain. Lanes: 1, 100-bp ladder; 2, M. tuberculosis; 3, M. africanum; 4, M. 
microti; 5, M. bovis; 6, M. kansasii; 7, M. avium; 8, M. intracellulare; 9, M. for-
tuitum; 10, negative control
1     2     3     4     5     6     7     8     9    10
500 ---
-- cfp32
-- RD9
RD12 -- RD12Nakajima et al. BMC Infectious Diseases 2010, 10:118
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study to see the prevalence of MTC species other than M.
tuberculosis  in clinical isolates in Bangladesh. The
method showed high specificity and sensitivity, as 99.1%
(347/350) of clinical M. tuberculosis isolates were identi-
fied by a typical banding pattern. It seemed to be very
useful as a routine test method because of its simplicity.
All the 350 MTC isolates derived from Bangladesh
patients were M. tuberculosis and no other MTC was
detected. The result suggested that a standard TB treat-
ment regimen including pyrazinamide can be applied to
the patients as the first choice in surveyed areas in Ban-
gladesh.
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